- If you are looking at HCA Healthcare and wondering whether the current share price still offers value, the recent numbers give you quite a bit to think about.
- The stock closed at US$493.88, with returns of 5.0% year to date and 51.2% over 1 year, while the last 7 and 30 days showed pullbacks of 7.3% and 7.7%.
- Recent coverage around HCA Healthcare has focused on its scale as a major hospital operator and its role in the broader US healthcare system. This often shapes how investors think about its resilience and growth options. At the same time, sector wide discussions on reimbursement, regulation, and healthcare demand have kept attention on how companies like HCA Healthcare are priced.
- On Simply Wall St's valuation checks, HCA Healthcare scores 5 out of 6. You can see how that is calculated in the valuation score. This sets up a closer look at traditional valuation methods next, along with a different way of thinking about fair value at the end of the article.
Approach 1: HCA Healthcare Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model projects a company’s future cash, meaning the cash it could return to shareholders, and then discounts those projections back to today to estimate what the business might be worth now.
For HCA Healthcare, the latest twelve month Free Cash Flow is about $7.4b. The Simply Wall St model uses a 2 Stage Free Cash Flow to Equity approach, combining analyst estimates and longer term extrapolations. Analyst inputs and extensions point to projected Free Cash Flow of $7.5b in 2026 and $8.3b by 2030, with later years gradually stepping up from that base.
After discounting these projected cash flows back to today, the model arrives at an estimated intrinsic value of about $890.11 per share. Compared with the recent share price of $493.88, this suggests HCA Healthcare trades at a 44.5% discount to the DCF estimate, which indicates the stock screens as materially undervalued on this cash flow view.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests HCA Healthcare is undervalued by 44.5%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.
Approach 2: HCA Healthcare Price vs Earnings
For profitable companies like HCA Healthcare, the P/E ratio is a commonly used way to think about valuation, because it tells you how much investors are paying for each dollar of current earnings. What counts as a “normal” P/E often reflects how the market views a company’s growth prospects and risk, with higher growth and lower perceived risk usually supporting a higher multiple.
HCA Healthcare currently trades on a P/E of 16.28x. That sits below the broader Healthcare industry average of 21.22x and also below the peer group average of 17.60x. Simply Wall St’s “Fair Ratio” for HCA Healthcare is 33.48x. This Fair Ratio is a proprietary estimate of what the P/E might be given factors such as the company’s earnings growth profile, its industry, profit margins, market cap and specific risks.
Comparing to the Fair Ratio can be more informative than just looking at peers or the sector because it adjusts for company specific characteristics rather than assuming that all firms in the same industry deserve similar multiples. With the current P/E of 16.28x sitting well below the Fair Ratio of 33.48x, the stock screens as undervalued on this earnings based view.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your HCA Healthcare Narrative
Earlier it was mentioned that there is an even better way to think about valuation, and that is where Narratives come in. Narratives let you attach a clear story about HCA Healthcare to the numbers you care about, such as your own view of fair value, revenue, earnings and margin estimates. You can then link that story to a financial forecast and a fair value that you can compare to today’s price on Simply Wall St’s Community page, where Narratives update as new news or earnings arrive. One investor might build a Narrative that leans on HCA’s scale, steady cash generation and the higher fair value estimate of about US$629.14. Another might focus on regulatory risks, Medicaid exposure and the lower analyst target of US$333.00. Seeing those side by side helps you decide whether the current share price looks high or low relative to the story you believe.
Do you think there's more to the story for HCA Healthcare? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com